Children

Despite limited evidence on its effectiveness in children, T-20 (enfuvirtide, Fuzeon) has been approved for use in children aged six years or older at a dose of 2mg/kg twice daily, up to a maximum of 90mg twice daily. This dose results in drug levels similar to those found in adults and is unaffected by age, weight, or developmental stage.1 The safety of T-20 in children and infants below six years of age is yet to be established.

Preliminary research has found that mild to moderate injection site reactions are common amongst children. Fever and wheezing were also reported.2

References

  1. Bellibas SE et al. Pharmacokinetics of enfuvirtide in pediatric human immunodeficiency virus 1-infected patients receiving combination therapy. Pediatr Infect Dis J 23: 1137-1141, 2004
  2. Church J et al. Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. Pediatr Infect Dis J 21: 653-659, 2002
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.